Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants

NCT ID: NCT02230046

Last Updated: 2016-01-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 102 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-31
• Study Completion Date: 2014-11-30

Brief Summary

The purpose of this study is to determine the bioequivalence (equivalence of pharmacokinetic parameters) of 2 abiraterone acetate coated tablet formulations with respect to the current commercial abiraterone acetate uncoated tablet formulation under fasted (without eating or drinking) conditions in healthy male participants.

Detailed Description

This is a Phase 1, randomized (study medication assigned to participants by chance), open-label (all people know the identity of the intervention), single-center, single-dose and 3-way Crossover (the same medications provided to all participants but in different sequence) pivotal study to determine the bioequivalence of 2 abiraterone acetate coated tablet formulations with respect to the current commercial abiraterone acetate uncoated tablet formulation. Approximately 102 healthy male participants will participate in this study. Participants will be randomly assigned to 1 of 6 treatment sequences. The study will consist of 3 parts: Screening Phase (within 21 days before the first study drug administration of the first period), an open-label treatment Phase consisting of 3 single-dose treatment periods (45 days) and follow-up Phase (5 to 7 days after the last study procedure). The total study duration for each participant will be from 45 days to a maximum of 61 days. Participants will receive a single oral 1000 milligram (mg) dose of abiraterone acetate under fasted conditions either as Treatment A (current commercial formulation, uncoated), Treatment B (current commercial formulation, coated) or Treatment C (new composition, coated). Bioequivalence will be primarily evaluated by pharmacokinetic parameters. Participants' safety will be monitored throughout the study.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Sequence 1 (ABC)

Participants will receive a single oral 1000 milligram \[mg\] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) in Period 1, Treatment B (current commercial formulation, 4\*250 mg coated tablets) in Period 2 and Treatment C (new composition, 2\*500 mg coated tablets) in Period 3.

Group Type: EXPERIMENTAL

Abiraterone acetate (Treatment A)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Abiraterone acetate (Treatment B)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Abiraterone acetate (Treatment B)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Sequence 2 (BCA)

Participants will receive a single oral 1000 milligram \[mg\] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4\*250 mg coated tablets) in Period 1, Treatment C (new composition, 2\*500 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) in Period 3.

Group Type: EXPERIMENTAL

Abiraterone acetate (Treatment A)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Abiraterone acetate (Treatment B)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Abiraterone acetate (Treatment B)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Sequence 3 (CAB)

Participants will receive a single oral 1000 milligram \[mg\] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2\*500 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) in Period 2 and Treatment B (current commercial formulation, 4\*250 mg coated tablets) in Period 3.

Group Type: EXPERIMENTAL

Abiraterone acetate (Treatment A)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Abiraterone acetate (Treatment B)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Abiraterone acetate (Treatment B)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Sequence 4 (ACB)

Participants will receive a single oral 1000 milligram \[mg\] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) in Period 1, Treatment C (new composition, 2\*500 mg coated tablets) in Period 2 and Treatment B (current commercial formulation, 4\*250 mg coated tablets) in Period 3.

Group Type: EXPERIMENTAL

Abiraterone acetate (Treatment A)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Abiraterone acetate (Treatment B)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Abiraterone acetate (Treatment B)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Sequence 5 (BAC)

Participants will receive a single oral 1000 milligram \[mg\] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment B (current commercial formulation, 4\*250 mg coated tablets) in Period 1, Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) in Period 2 and Treatment C (new composition, 2\*500 mg coated tablets) in Period 3.

Group Type: EXPERIMENTAL

Abiraterone acetate (Treatment A)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Abiraterone acetate (Treatment B)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Abiraterone acetate (Treatment B)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Sequence 6 (CBA)

Participants will receive a single oral 1000 milligram \[mg\] dose of abiraterone acetate in all 3 periods under fasted conditions as: Treatment C (new composition, 2\*500 mg coated tablets) in Period 1, Treatment B (current commercial formulation, 4\*250 mg coated tablets) in Period 2 and Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) in Period 3.

Group Type: EXPERIMENTAL

Abiraterone acetate (Treatment A)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Abiraterone acetate (Treatment B)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Abiraterone acetate (Treatment B)

Intervention Type: DRUG

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Interventions

Abiraterone acetate (Treatment A)

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4\*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention Type: DRUG

Abiraterone acetate (Treatment B)

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4\*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention Type: DRUG

Abiraterone acetate (Treatment B)

Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2\*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.

Intervention Type: DRUG

Other Intervention Names

JNJ-212082; JNJ-212082; JNJ-212082

Eligibility Criteria

Inclusion Criteria

• If sexually active, participants must always use a condom during the study and for 1 week after last intake of study drug. If sexually active with a pregnant woman or woman of child-bearing potential, participants must agree to abstain from intercourse during the study and for 1 week after last intake of study drug. Participants should not donate sperm during the study and for 1 week after receiving the last dose of study drug
• Body mass index (BMI; weight [kilogram(kg)]/height^2 [meter square (m^2)]) between 18.5 and 30.0 kg/m^2, (inclusive), and body weight not less than 50 kg
• Blood pressure (after the participants is supine for 5 minutes) between 90 and 140 millimeter of mercury (mmHg) systolic, inclusive, and no higher than 90 mmHg diastolic at Screening
• A 12-lead electrocardiogram (ECG) consistent with normal cardiac conduction and function at Screening as specified in the protocol
• Non-smoker, no history of smoking or use of nicotine-containing substances within the previous 2 months, as determined by medical history or participant's verbal report

Exclusion Criteria

• History of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participants or that could interfere with the interpretation of the study results
• Clinically significant abnormal values for hematology or clinical chemistry at Screening
• Presence of sexual dysfunction (abnormal libido, erectile dysfunction, etc.) or any medical condition that would affect sexual function
• Use of any prescription or nonprescription medication (including vitamins and herbal supplements), except for acetaminophen, within 14 days before the first dose of the study drug is scheduled through study completion
• History of, or a reason to believe a participants has a history of drug or alcohol abuse within the past 5 years

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janssen Research & Development, LLC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Tempe, Arizona, United States

Countries

United States

Other Identifiers

212082PCR1007

Identifier Type: OTHER

Identifier Source: secondary_id

CR105286

Identifier Type: -

Identifier Source: org_study_id